journal article·2020-12-05

Injectable graphite-modified Fe3O4/calcium phosphate bone cement with enhanced heating ability for hyperthermia

Kaili Zhang, Guangda Li, Zhengjun Pei, Santuan Zhao, Aihua Jing, Gaofeng Liang

Materials Technology· Volume 35· Issue 13-14
Publisher page

Abstract

Graphite-modified magnetite (Fe3O4) has been incorporated to brushite bone cement to prepare novel injectable magnetic bone cement (NIMC) for hyperthermia. The results reveal that NIMC with a setting time of 30 min is injectable and anti-washout. Under the magnetic field of 1.59 × 106 A/m, the saturation magnetisation of NIMC is 28.01 A·m2/Kg, higher than that of the contrast with non-modified magnetite. Moreover, after exposed to an alternating magnetic field (340 kHz, 1.13 × 103 A/m) for 200 s, the specific absorption rate values of NIMC and the contrast are 30.20 W/g and 18.75 W/g, respectively. NIMC displays much better heating ability than the contrast. Moreover, IMBC has no cytotoxicity to MG-63 cells, and MG-63 cells can adhere and spread on the cement after co-culturing for 7 days. Therefore, this novel magnetic bone cement has the potential to be used for hyperthermia.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bone Tissue Engineering Materials · Nanoparticle-Based Drug Delivery · Parathyroid Disorders and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

College of Medical Technology and Engineering, Henan University of Science and Technology, Luo Yang, Henan, China

College of Material Science and Engineering, Henan University of Science and Technology, Luo Yang, Henan, China

Medicine College, Henan University of Science and Technology School, Luo Yang, Henan, China

Funding

Natural Science Foundation of China · Young Backbone Teachers Project in Henan Higher Education Institution, China · Scientific and Technological Research Projects of Henan Province, China

References (26)

Show source-provided references
1. 10.1016/j.critrevonc.2005.03.01110.1016/j.critrevonc.2005.03.011 ↗
2. 10.1007/s10147-011-0217-310.1007/s10147-011-0217-3 ↗
3. 10.1007/s00590-014-1468-210.1007/s00590-014-1468-2 ↗
4. Tsukahara TWada T. Immunotherapy for osteosarcoma. Osteosarcoma. In: Ueda T, Kawai A. (eds). Osteosarcoma. Springer, Tokyo. 2016; 31–4110.1007/978-4-431-55696-1_3 ↗
5. Wensheng X · J Mod Oncol · 2018 · 26 · 454
6. 10.20517/2394-4722.2017.3510.20517/2394-4722.2017.35 ↗
7. 10.1016/j.actbio.2010.02.04710.1016/j.actbio.2010.02.047 ↗
8. 10.1063/1.497349910.1063/1.4973499 ↗
9. 10.1039/C6RA20860F10.1039/C6RA20860F ↗
10. 10.1016/j.apenergy.2015.01.02210.1016/j.apenergy.2015.01.022 ↗
11. Guangda L · Ceram Int · 2018 · 45 · 4945
12. 10.1016/j.matlet.2017.12.05410.1016/j.matlet.2017.12.054 ↗
13. 10.1177/088532821880801510.1177/0885328218808015 ↗
14. Jiandon Y · J Fun Mater · 2008 · 39 · 271
15. 10.15541/jim2013062510.15541/jim20130625 ↗
16. 10.1016/j.jmmm.2015.03.08510.1016/j.jmmm.2015.03.085 ↗
17. 10.1016/j.jmmm.2018.09.11110.1016/j.jmmm.2018.09.111 ↗
18. Vlad MD · J Mater Sci · 2008 · 19 · 3575
19. 10.1016/j.msec.2016.09.03010.1016/j.msec.2016.09.030 ↗
20. 10.1007/s10853-016-0017-210.1007/s10853-016-0017-2 ↗
21. 10.1142/S179329201100246910.1142/S1793292011002469 ↗
22. Runsheng W · J Tissue Eng Res · 2019 · 23 · 2921
23. Zhang P · Bio Chem Eng · 2017 · 3 · 53
24. 10.1016/j.ijmachtools.2015.11.00410.1016/j.ijmachtools.2015.11.004 ↗
25. 10.1016/j.ceramint.2012.11.01710.1016/j.ceramint.2012.11.017 ↗
26. 10.1021/acsami.5b0207710.1021/acsami.5b02077 ↗